A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
A phase 2 trial of Volrustomig in cervical cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) is a phase 2 interventional study registered as NCT06943833 by AstraZeneca, with 37 participants enrolled, started 2025-03-31 and due to reach its primary completion in 2028-03-13. Interventions recorded: Volrustomig.
Similar pages
not linked directly; found by shared links- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares AstraZeneca, Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares AstraZeneca and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca and the tag pipeline.
- TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Shares AstraZeneca and the tag pipeline.
- TrialA Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Shares AstraZeneca and the tag pipeline.